Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Marketing of Imusera, Telavic to Be Limited to Specialists at First: MTPC
November 2, 2011
- Daiichi Sankyo Reports Decreases in Sales, Profits in Apr-Sept Term by Slump of Ranbaxy, Return of Marketing Rights
November 1, 2011
- MTPC: Profits Down but Remicade, Generics Show Steady Growth in Apr-Sept
November 1, 2011
- DSP to Boost Domestic CNS Business for Early Maximization of Lonasen
November 1, 2011
- Shionogi’s Strength in Japan Weakened by Slack US Results, Overall Sales Down 13.5% in Apr-Sept
November 1, 2011
- Sharp Decrease in Profits due to Declines in License Revenues: JCR’s Half year Financial Report
November 1, 2011
- Zeria Upwardly Revises Profits forecasts for 1st Half of FY2012
November 1, 2011
- Mochida: Epadel, Lexapro Drive Growth in 1st-Half Sales and Profits
November 1, 2011
- DSP: Strong Yen Contributes to 5.6% Decline in Sales
November 1, 2011
- Further Deterioration in Sales Prices Unlikely in 2nd Half: President Watanabe of Mediceo
November 1, 2011
- Three Top Dispensing Pharmacy Chains Report 50% Growth in Operating Profits
November 1, 2011
- ASKA Downwardly Revises Sales Forecast Due to Effects of Quake
October 31, 2011
- Astellas Upwardly Revises Business Forecasts Driven by Vesicare
October 31, 2011
- Abilify Posted US Sales of US$983 Mil. in Jul-Sep
October 31, 2011
- Anti-HIV JTK-303 Applied for Combination Tablet in the US: JT
October 31, 2011
- Losses Increase Due to Fallen Milestone Payments: OncoTherapy
October 31, 2011
- Wakamoto’s Apr-Sep Profits Up 2% on Latanoprost Sales Growth, Recovered Losses
October 31, 2011
- Terumo Posts Record Sales, Operating Profits in First Half FY2012
October 31, 2011
- PI Trial of Darinaparsin Inj. Starts for PTCL: Solasia
October 31, 2011
- MediciNova to Start Repeat Dose PIb Clinical Trial of MN-221 in US
October 31, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…